Citius Pharmaceuticals (Warrant)

$1.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-8.70%) As of 4:34 PM UTC today

Why Robinhood?

You can watch CTXRW and buy or sell other stocks, options, and ETFs commission-free!

About CTXRW

Citius Pharmaceuticals, Inc. Warrant, also called Citius Pharmaceuticals (Warrant), is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. The listed name for CTXRW is Citius Pharmaceuticals, Inc. Warrant.

CEO
Myron Z. Holubiak
Employees
—
Headquarters
Cranford, New Jersey
Founded
2007
Market Cap
—
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
118.20K
High Today
$1.56
Low Today
$1.17
Open Price
$1.52
Volume
23.68K
52 Week High
$2.89
52 Week Low
$0.1124

You May Also Like

NPSNY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure